Home   Business   Article

Subscribe Now

ELRIG UK’s partnership with SRG is good news for early careers




Science is the beneficiary as the European Laboratory Research & Innovation Group (ELRIG) UK enters into a partnership with SRG, leaders in life science recruitment.

ELRIG UK is a not-for-profit, volunteer-led organisation for the drug discovery community based at Salisbury House on Station Road.

Melanie Leveridge, chair, ELRIG UK, and Vice President Discovery Biology, AstraZeneca
Melanie Leveridge, chair, ELRIG UK, and Vice President Discovery Biology, AstraZeneca

The partnership offers the ELRIG community access to career opportunities and provides organisations of all sizes with SRG’s specialist talent solutions to help grow the life science sector. In particular, early career professionals (ECPs) in industry and academia can attend forums and networking events where they can meet, and learn the skills needed to help them advance their careers in drug discovery.

Andrew Turner, managing director, SRG, said: “Our partnership with ELRIG, an organisation that shares our passion for innovation, will focus on talent enablement, and supporting the advancement of science professionals at each stage of their career.”

Sanj Kumar, CEO, ELRIG UK, said: “ELRIG and SRG have a shared ambition to advance the careers of early-stage professionals in drug discovery. ELRIG will provide the opportunities for ECPs to connect, whilst SRG can help them to expand their skillset and progress in their careers.

Sanj Kumar, CEO, ELRIG UK
Sanj Kumar, CEO, ELRIG UK

“Building such networks is an imperative as they navigate the myriad of collaboration and career options ahead of them. We are delighted to be working with the team at SRG, who bring 30 years of industry experience supporting scientific endeavours to this exciting collaboration.”

As part of its commitment to ECPs (early career professionals), ELRIG is hosting a webinar at 1pm on 24 April titled ‘AI at the Frontier: Empowering Early Career Professionals in Drug Discovery’.

The session includes a panel discussion and a Q&A.

More detail here.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More